Session » Rheumatoid Arthritis - Clinical Aspects II: Infection, Malignancy and Other Comorbidites in RA

Date: Monday, November 9, 2015

Time: 2:30PM-4:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

Abstract Number: 2048

Hospitalization Trends of Rheumatoid Arthritis and Gout in the United States: A Crossroad

Abstract Number: 2049

Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases

Abstract Number: 2050

Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy

Abstract Number: 2051

Risk for Lower Intestinal Perforations in RA Patients Treated with Tocilizumab in Comparison to Treatment with TNF Inhibitors, Rituximab, Abatacept or Conventional Synthetic Dmards

Abstract Number: 2052

Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes

Abstract Number: 2053

Adjustment of Skeletal Muscle Mass Estimates for the Extent of Adiposity Strengthens Relationships with Functional Outcomes in Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.